Wireless Glucose Monitoring in Type I Diabetes Patients

Student Team 4SITe
Tuesday, November 22, 2011 - 6:30pm

Diabetes is a chronic disease affecting nearly 26 million people in the United States and this number continues to grow.  Approximately 5-10% of these patients have Type 1 Diabetes resulting in the inability of pancreatic beta cells to produce insulin, a hormone required in the regulation of carbohydrate metabolism. The regulation of carbohydrates is lost in diabetic patients leading to uncontrolled levels of glucose in the blood. Constant monitoring of blood glucose is therefore necessary in order to effectively manage the disease; improper management may lead to various underlying complications including cardiovascular disease, blindness, and renal failure. Current treatment and management options include insulin therapy and glucose monitoring.

Medtronic is one of the current market leaders in continuous glucose monitoring (CGM), representing one of the latest advancements in diabetes treatment options; however, the market penetration of CGMs remains relatively low. Reasons for low penetration can be linked to low patient compliance and lack of user friendliness. With the current trends in wireless healthcare solutions, we believe Medtronic can take advantage of Bluetooth® technology in conjunction with smartphone mobile applications to enhance user experience with their CGM devices, providing patients with a more convenient and discrete method of monitoring their diabetes. With the increasing trend in Smartphone usage along with the increasing adoption of CGM devices, we propose a model that demonstrates how implementation of Bluetooth® technology in Medtronic’s MiniMed Paradigm® Revel™ device will provide an opportunity for Medtronic to increase CGM market share and attain a high return on investment.

Astra Zeneca Seminars. Tuesday, November 22, 2011, 6:30pm, Room IB335. All welcome!